Switch theme
Sign up to access all valuation multiples
Hubei Jumpcan Pharmaceutical Co Ltd engages in the research, development, manufacturing, and trading of Chinese traditional medicines, western medicines, daily use chemicals based on Chinese traditional medicines, and Chinese medicine health products in China. It offers Chinese and Western medicines in the areas of pediatrics, gynecology, pneumology, gastroenterology, and geriatric. The company also develops Chinese and western medicines in the areas of detoxification, digestive system, respiratory system, nervous system, anti-infection, cardiovascular, narcotic analgesic, nutrition, musculoskeletal, and hemostasis.
1997
5.2K+
LTM Revenue n/a
LTM EBITDA n/a
$2.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Hubei Jumpcan has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Hubei Jumpcan achieved revenue of $1.3B and an EBITDA of $498M.
Hubei Jumpcan expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Hubei Jumpcan valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.3B | n/a | XXX | XXX | XXX |
| Gross Profit | $875M | $1.0B | XXX | XXX | XXX |
| Gross Margin | 66% | NaN% | XXX | XXX | XXX |
| EBITDA | $498M | n/a | XXX | XXX | XXX |
| EBITDA Margin | 37% | NaN% | XXX | XXX | XXX |
| Net Profit | $237M | $299M | XXX | XXX | XXX |
| Net Margin | 18% | NaN% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Hubei Jumpcan's stock price is CNY 27 (or $4).
Hubei Jumpcan has current market cap of CNY 24.9B (or $3.4B), and EV of CNY 14.4B (or $2.0B).
See Hubei Jumpcan trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.0B | $3.4B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Hubei Jumpcan has market cap of $3.4B and EV of $2.0B.
Hubei Jumpcan's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Hubei Jumpcan's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Hubei Jumpcan and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.0B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpHubei Jumpcan's NTM/LTM revenue growth is n/a
Hubei Jumpcan's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Hubei Jumpcan's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Hubei Jumpcan's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Hubei Jumpcan and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 40% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 51% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hubei Jumpcan acquired XXX companies to date.
Last acquisition by Hubei Jumpcan was XXXXXXXX, XXXXX XXXXX XXXXXX . Hubei Jumpcan acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Hubei Jumpcan founded? | Hubei Jumpcan was founded in 1997. |
| Where is Hubei Jumpcan headquartered? | Hubei Jumpcan is headquartered in China. |
| How many employees does Hubei Jumpcan have? | As of today, Hubei Jumpcan has 5.2K+ employees. |
| Is Hubei Jumpcan publicy listed? | Yes, Hubei Jumpcan is a public company listed on SHG. |
| What is the stock symbol of Hubei Jumpcan? | Hubei Jumpcan trades under 600566 ticker. |
| When did Hubei Jumpcan go public? | Hubei Jumpcan went public in 2001. |
| Who are competitors of Hubei Jumpcan? | Similar companies to Hubei Jumpcan include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Hubei Jumpcan? | Hubei Jumpcan's current market cap is $3.4B |
| Is Hubei Jumpcan profitable? | Yes, Hubei Jumpcan is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
